The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | March 2008 |
| End Date: | December 2013 |
| Contact: | Barbara Hall, LPN |
| Phone: | 716-887-5104 |
Sitagliptin is a new oral hypoglycemic anti-diabetic drug used either alone or in
combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus.
Sitagliptin has been shown to have fewer side effects in the control of blood glucose
values.
Obesity and diabetes are states of increased inflammation and can influence the free
radicals and inflammatory markers (chemicals in the blood which increase due to inflammation
in the body) and are also major risk factors for atherosclerotic disease. In this study we
want to see the effect of sitagliptin on these markers. We believe that Sitagliptin may
exert an anti-inflammatory effect in the human. The purpose of this study is to determine if
the addition of sitagliptin to diabetic patients will provide added benefit. We believe that
sitagliptin provides these added benefits by suppressing free radicals (charged substances
that cause damage to the body) and inflammation.
Inclusion Criteria:
- Males or females with age 20-75 years inclusive.
- Type 2 diabetes
- Males and Females BMI > 30
- Subjects on statins, ACE inhibitors, thiazolidenediones and antioxidants will be
allowed as long as they are on stable doses of these compounds and the dosage in not
changed during the course of study.
- BP under control -No change required to BP medications
- HbA1c > 7%
Exclusion Criteria:
- Coronary event or procedure (myocardial infarction, unstable angina, coronary artery
bypass, surgery or coronary angioplasty) in the previous four weeks
- Pregnancy
- Hepatic disease (abnormal LFT's),Renal impairment (serum creatinine > 1.5),
- Participation in any other concurrent clinical trial
- Any other life-threatening, non-cardiac disease,
- Uncontrolled hypertension (BP > 160/100 mm of Hg)
- Congestive Heart Failure
- Use of an investigational agent or therapeutic regimen within 30 days of study
- Subjects on Exenatide, incretin or insulin therapy
We found this trial at
1
site
Click here to add this to my saved trials
